Yale Cancer Center Study Shows Checkpoint Inhibitor Prolongs Survival in Patients With Certain Head and Neck Cancers
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC).
Smilow Cancer Hospital celebrates 10th anniversary
Smilow Cancer Hospital at Yale New Haven celebrates 10 years since it opened its doors to a new state-of-the-art inpatient and outpatient 500,000-square-foot cancer care facility. Since that day in October 2009, Smilow Cancer Hospital and Yale Cancer Center have risen to the top echelon as one of the nation’s comprehensive cancer research and care facilities, providing advanced care to patients and families and pioneering cancer research.
Yale Scientists Help Immune System Find Hidden Cancer Cells
Cancer cells are masters at avoiding detection, but a new system developed by Yale Cancer Center scientists can make them stand out from the crowd and help the immune system spot and eliminate tumors that other forms of immunotherapies might miss, the researchers report Oct. 14 in the journal Nature Immunology.
Applications Being Accepted for Pershing Square Sohn Prize for Young Investigators in Cancer Research
The Pershing Square Sohn Prize for Young Investigators in Cancer Research provides early career scientists based in greater New York City (a region that includes New Haven) the freedom to take risks and pursue their boldest research at a stage when traditional funding is lacking. Prize winners each receive $200,000 a year for up to three years, totaling $600,000. At least six prizes are awarded annually.
Once-Common Hysterectomy Technique Linked to Worse Uterine Cancer Outcomes
Every year, nearly 700,000 American women have surgery to remove their uterus (hysterectomy) or uterine fibroids (myomectomy). A laparoscopic surgical technique once commonly used in these procedures could be worsening the outcomes for women who have undiagnosed uterine cancer at the time of the procedure, Yale Cancer Center scientists report in the Journal of Clinical Oncology.
HEALTH NOTES: Black and Hispanic Cancer Patients Are Underrepresented in Clinical Trials
A new study has shown that clinical trials for new cancer medications rarely analyze data on safety and effectiveness by race and that black and Hispanic patients are consistently underrepresented among participants.
Yale Cancer Center Researchers Show Adding Radiation After Immunotherapy Improves Survival Time for Patients with Advanced Lung Cancer
The results of a phase II clinical trial by Yale Cancer Center (YCC) researchers show adding high-dose radiation after immunotherapy stops working increases survival time for patients with metastatic non-small-cell lung cancer (NSCLC).